Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Description:**\n2',5'-Dideoxy-Adenosine 3'-Monophosphate is a synthetic nucleoside monophosphate analog of adenosine. It belongs to the class of ribonucleoside phosphates and is characterized by the absence of hydroxyl groups at the ribose positions C'₂ and C'₅. This compound has been primarily used as an experimental tool in biochemical research rather than as a therapeutic agent. Its main mechanism involves acting as an inhibitor of adenylyl cyclase (also known as adenylate cyclase), thereby reducing cellular cyclic AMP (cAMP) levels. By mimicking natural nucleotides but lacking key functional groups required for enzymatic activity or further phosphorylation/elongation in nucleic acids or signaling pathways, it serves to block cAMP-mediated signal transduction[1][7]. There are no approved clinical indications for this molecule; it is classified as an experimental small molecule[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2',5'-dideoxy-adenosine 3'-monophosphate.